argenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024. In the quarter to June 2026, revenue grew 59.5%, EPS grew 88.6% and free cash flow grew 537.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow ARGX
argenex SE (ARGX) EV/Sales
As of 16 October 2026, argenex SE (ARGX) trades at a EV/Sales of 8.9×. Over the past ten years it has ranged from 0.0× (March 2020) to 165× (February 2021); the current reading is higher than 31% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 11.3× | (27.86%) |
| FY2024 | 15.7× | 0.80% |
| FY2023 | 15.6× | (64.53%) |
| FY2022 | 43.9× | 81.24% |
| FY2021 | 24.2× | (80.25%) |
| FY2020 | 123× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 10.2× | 15.66% |
| Mar 2026 | 8.8× | (22.22%) |
| Dec 2025 | 11.3× | (3.42%) |
| Sep 2025 | 11.7× | 15.85% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| INCY Incyte Corporation compare | 3.1× |
| REGN Regeneron Pharmaceuticals, Inc. compare | 4.9× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.0× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.1× |
| ARGX argenex SE | 8.9× |
| RPRX Royalty Pharma PLC compare | 14.0× |
| MRNA Moderna, Inc. compare | 36.9× |
| RVMD Revolution Medicines, Inc. compare | 1,287× |
| ROIV Roivant Sciences Ltd. compare | 2,742× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)